Pipeline
Anti-CEACAM6 ADC
Antibody-drug conjugates (ADCs) represent a next-generation targeted therapy that combines the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapy. By selectively targeting tumor-associated antigens, ADCs enhance drug delivery to cancer cells while minimizing systemic toxicity. CEACAM6 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6) is a well-characterized tumor-associated antigen that is overexpressed in multiple solid tumors, including colorectal and pancreatic cancers. Our Anti-CEACAM6 ADC platform is designed to selectively target CEACAM6-expressing tumor cells, delivering a potent cytotoxic payload to induce tumor cell death.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-ADC001
Colorectal cancer
JY-ADC002
Pancreatic cancer
JY-ADC001 (Colorectal Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-ADC001
Colorectal cancer
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide and a leading cause of cancer-related mortality. Despite advances in targeted therapies and immunotherapy, patients with metastatic or relapsed disease often face limited treatment options. JY-ADC001 is our Anti-CEACAM6 ADC therapy being developed for the treatment of colorectal cancer. By targeting CEACAM6-expressing tumor cells, JY-ADC001 aims to provide a more precise and effective treatment strategy while reducing off-target toxicity associated with traditional chemotherapy. Preclinical studies have demonstrated promising tumor-targeting capabilities of JY-ADC001. We are advancing this therapy towards early-phase clinical trials, focusing on evaluating its safety, tolerability, and efficacy in patients with CEACAM6-positive colorectal cancer.
JY-ADC002 (Pancreatic Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
JY-ADC002
Pancreatic cancer
Pancreatic cancer remains one of the most aggressive and deadly malignancies, characterized by late-stage diagnosis, rapid progression, and resistance to conventional therapies. The overexpression of CEACAM6 in pancreatic tumors makes it a highly relevant target for ADC-based therapies. JY-ADC002 is our Anti-CEACAM6 ADC therapy designed for the treatment of pancreatic cancer. The goal is to selectively eliminate CEACAM6-expressing tumor cells while sparing normal tissues, thereby enhancing therapeutic efficacy and reducing systemic toxicity. We are advancing JY-ADC002 through preclinical and early clinical development, with the objective of establishing a novel targeted therapy for pancreatic cancer patients who have limited treatment options.